Full Press Release Details
Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Fla., October 6, 2025 (GLOBE NEWSWIRE) -Dyadic Applied BioSolutions ("Dyadic", "we", "us",
"our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free
proteins and enzymes for diverse commercial applications today announced the achievement of additional milestone payments in its collaborations
with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, along with updates on its business transformation
and commercial progress.
is advancing its transition to a commercially focused, revenue-driven company, said Joe Hazelton, Dyadic Applied BioSolutions President
and Chief Operating Officer. "The third quarter featured substantial progress throughout our portfolio, marked by notable achievements
in partnerships with Proliant Health and Biologicals in the life sciences sector, as well as ongoing collaborations with Inzymes in food
and nutrition. These accomplishments highlight the versatility and scalability of Dyadic's protein production platforms across
multiple markets. The company remains committed to capitalizing on near-term commercialization opportunities, supported by a stronger
balance sheet and an expanding pipeline of both partner-led and internally developed products".
Company Developments
| Recombinant Human Albumin (Proliant Partnership): In Q3 2025, Dyadic reached a milestone in productivity, achieving a $500,000 milestone, with payment anticipated in Q4 2025. Additional revenue growth is expected as commercialization advances. Proliant has started sampling the product, with the commercial launch targeted for late 2025 and early 2026. | ||
| Recombinant Transferrin: Sampling efforts are expanding in research, diagnostic and cultured meat markets. Initial production of lab-grade non-animal transferrin products is underway to meet current OEM and supply opportunities. Validation is ongoing with research and diagnostic customers. | ||
| Recombinant DNase I (RNase-free): Dyadic's DNase I has successfully met required performance benchmarks for activity and purity, validating its utility in molecular biology, diagnostics, and biopharma applications. Dyadic is currently producing its DNase I at research grade to support direct sales and OEM supply opportunities. |
| Recombinant Alpha-Lactalbumin: A term sheet has been signed for the development of non-animal human alpha-lactalbumin for use in the infant nutrition market. Initial sampling of non-animal bovine alpha-lactalbumin for food and nutrition markets is in progress, and licensing discussions are underway with potential partners. | ||
| Non-Animal Dairy Enzymes (Inzymes Partnership): Dyadic received a $250,000 milestone payment following the achievement of productivity improvements in Q3 2025. The first enzyme's scale-up is on track for a late 2025 launch, with additional enzyme candidates advancing as part of this partnership. |
Dyadic Applied BioSolutions
Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins
that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins
are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus
expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered
programs. For more information about Dyadic, please visit www.dyadic.com.
Harbor Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events
or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research
projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks,
uncertainties or other factors beyond Dyadic's control. These factors include, but are not limited to, the following: (i) our history
of net losses (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies
(iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from
alternative technologies (v) the results of nonclinical studies and clinical trials (vi) our capital needs (vii) changes
in global economic and financial conditions (viii) our reliance on information technology (ix) our dependence on third parties
(x) government regulations and environmental, social and governance issues (xi) intellectual property risks; and (xii) our ability
to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's
annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in
Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com. All forward-looking
statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update
any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results
or to changes in our expectations.